|
|
Post by rfogel on Jan 15, 2021 9:10:47 GMT -5
I don't quite understand. Cannabidiol is described as a "non-psychoactive compound," so how does it affect anxiety? |
|
|
|
Post by cretin11 on Jan 15, 2021 12:29:42 GMT -5
I don't quite understand. Cannabidiol is described as a "non-psychoactive compound," so how does it affect anxiety? It reduces anxiety without the “high” associated with THC. That high is what’s meant by “psychoactive” in this case. |
|
|
|
Post by mango on Jan 18, 2021 13:03:02 GMT -5
I don't quite understand. Cannabidiol is described as a "non-psychoactive compound," so how does it affect anxiety? Cannabidiol is psychoactive. What they most likely meant was it is non-intoxicating. |
|
|
|
Post by MnkdWASmyRtrmntPlan on Jan 18, 2021 18:51:32 GMT -5
Right, Mango ... www.cannabisbusinessexecutive.com/2019/05/its-time-to-set-the-record-straight-cbd-is-psychoactive/?utm_source=Mondaq&utm_medium=syndication&utm_campaign=LinkedIn-integrationThe media loves to say that CBD (cannabidiol) is “non-psychoactive.” The frequency with which this statement is repeated rises with the popularity of CBD. Most commentators who use the term “non-psychoactive” likely mean to say that CBD is “not intoxicating,” which is certainly true. But CBD is psychoactive.
A chemical is considered psychoactive when it acts primarily on the central nervous system and alters brain function, resulting in temporary changes in perception, mood, consciousness or behavior.CBD does not have the intoxicating effect of THC and does not result in obvious cognitive alterations or withdrawal effects. CBD does, however, cross the blood-brain barrier and it directly affects the central nervous system with resulting changes in mood and perception.
|
|
|
|
Post by goyocafe on Jan 19, 2021 9:05:25 GMT -5
I guess things are starting to happen in earnest at RLS. New CEO...New homepage (again)... www.receptorlife.com/Oddly, they’ve gone out of their way to hide the URLs of their website pages and only present the main URL. Check out their press releases. It’s news as of today, 1/19/2021. JAN 19, 2021 | Press Release Receptor Life Sciences Names Successful Pharmaceutical Industry Executive, Mark Theeuwes, President and Chief Executive Officer SEATTLE – Receptor Life Sciences ("RLS") today announced the appointment of Mark Theeuwes as President, Chief Executive Officer and member of the Board of Directors of RLS. Mr. Theeuwes will succeed Greg Wesner, who co-founded Receptor in 2015 and has served as CEO and Director since its inception. Mr. Wesner will remain on the Board of Directors of RLS. "RLS is at an important inflection point with our delivery technologies expected to have INDs in 2021. Mark is an experienced pharmaceutical executive with a proven track record of building clinical and commercial stage organizations. Under Mark’s leadership, RLS is well-positioned for continued success," said Arthur Rubinfeld, Executive Chairman of RLS. Mr. Theeuwes joins RLS following the acquisition of Engage Therapeutics ("Engage") by UCB in June 2020. He served as Chief Operating Officer from 2018 until its acquisition, which came following positive data from a large, randomized Phase 2 clinical trial of its lead product candidate in development for a new product category called REST (Rapid Epileptic Seizure Termination). Prior to joining Engage, Mr. Theeuwes held positions of increasing responsibility at Egalet, NPS (acquired by Shire), ViroPharma (acquired by Shire), OraPharma (acquired by Valeant), Johnson & Johnson and Alza (acquired by J&J). "I am honored and excited to lead RLS and build upon the solid foundation that Greg and the team have established over the last five years," said Mr. Theeuwes. "Receptor has two promising clinical candidates in its pipeline that may favorably impact millions of patients who today have inadequate therapies. I look forward to progressing the pipeline to bring these therapies to patients in need." Contact for Media: Mark Theeuwes mtheeuwes@receptorlife.com As far as I can tell this “PR” was not put out on the wire for the media. |
|
|
|
Post by uvula on Jan 19, 2021 9:44:47 GMT -5
Based on the new CEO's track record, the next press release will say "RLS is being acquired by..."
|
|
|
|
Post by mnkdfann on Jan 19, 2021 10:21:14 GMT -5
I guess things are starting to happen in earnest at RLS. New CEO...New homepage (again)... www.receptorlife.com/Oddly, they’ve gone out of their way to hide the URLs of their website pages and only present the main URL. Check out their press releases. It’s news as of today, 1/19/2021. JAN 19, 2021 | Press Release Receptor Life Sciences Names Successful Pharmaceutical Industry Executive, Mark Theeuwes, President and Chief Executive Officer SEATTLE – Receptor Life Sciences ("RLS") today announced the appointment of Mark Theeuwes as President, Chief Executive Officer and member of the Board of Directors of RLS. Mr. Theeuwes will succeed Greg Wesner, who co-founded Receptor in 2015 and has served as CEO and Director since its inception. Mr. Wesner will remain on the Board of Directors of RLS. "RLS is at an important inflection point with our delivery technologies expected to have INDs in 2021. Mark is an experienced pharmaceutical executive with a proven track record of building clinical and commercial stage organizations. Under Mark’s leadership, RLS is well-positioned for continued success," said Arthur Rubinfeld, Executive Chairman of RLS. Mr. Theeuwes joins RLS following the acquisition of Engage Therapeutics ("Engage") by UCB in June 2020. He served as Chief Operating Officer from 2018 until its acquisition, which came following positive data from a large, randomized Phase 2 clinical trial of its lead product candidate in development for a new product category called REST (Rapid Epileptic Seizure Termination). Prior to joining Engage, Mr. Theeuwes held positions of increasing responsibility at Egalet, NPS (acquired by Shire), ViroPharma (acquired by Shire), OraPharma (acquired by Valeant), Johnson & Johnson and Alza (acquired by J&J). "I am honored and excited to lead RLS and build upon the solid foundation that Greg and the team have established over the last five years," said Mr. Theeuwes. "Receptor has two promising clinical candidates in its pipeline that may favorably impact millions of patients who today have inadequate therapies. I look forward to progressing the pipeline to bring these therapies to patients in need." Contact for Media: Mark Theeuwes mtheeuwes@receptorlife.com As far as I can tell this “PR” was not put out on the wire for the media. Wasn't too hard to find, it was out for the media as of at least 8 am EST: www.businesswire.com/news/home/20210119005088/en/Receptor-Life-Sciences-Names-Successful-Pharmaceutical-Industry-Executive-Mark-Theeuwes-President-and-Chief-Executive-Officer |
|
|
|
Post by harryx1 on Jan 19, 2021 10:47:56 GMT -5
|
|
|
|
Post by kite on Jan 19, 2021 10:49:18 GMT -5
|
|
|
|
Post by kite on Jan 19, 2021 11:00:20 GMT -5
JAN 19, 2021 | Press Release Receptor Life Sciences Names Successful Pharmaceutical Industry Executive, Mark Theeuwes, President and Chief Executive Officer
SEATTLE – Receptor Life Sciences ("RLS") today announced the appointment of Mark Theeuwes as President, Chief Executive Officer and member of the Board of Directors of RLS. Mr. Theeuwes will succeed Greg Wesner, who co-founded Receptor in 2015 and has served as CEO and Director since its inception. Mr. Wesner will remain on the Board of Directors of RLS. "RLS is at an important inflection point with our delivery technologies expected to have INDs in 2021. Mark is an experienced pharmaceutical executive with a proven track record of building clinical and commercial stage organizations. Under Mark’s leadership, RLS is well-positioned for continued success," said Arthur Rubinfeld, Executive Chairman of RLS. Mr. Theeuwes joins RLS following the acquisition of Engage Therapeutics ("Engage") by UCB in June 2020. He served as Chief Operating Officer from 2018 until its acquisition, which came following positive data from a large, randomized Phase 2 clinical trial of its lead product candidate in development for a new product category called REST (Rapid Epileptic Seizure Termination). Prior to joining Engage, Mr. Theeuwes held positions of increasing responsibility at Egalet, NPS (acquired by Shire), ViroPharma (acquired by Shire), OraPharma (acquired by Valeant), Johnson & Johnson and Alza (acquired by J&J). "I am honored and excited to lead RLS and build upon the solid foundation that Greg and the team have established over the last five years," said Mr. Theeuwes. "Receptor has two promising clinical candidates in its pipeline that may favorably impact millions of patients who today have inadequate therapies. I look forward to progressing the pipeline to bring these therapies to patients in need." Contact for Media: Mark Theeuwes mtheeuwes@receptorlife.com ABOUT RECEPTOR HOLDINGS AND RECEPTOR LIFE SCIENCES Seattle-based RHI owns or exclusively licenses drug delivery technologies enabling high bioavailability, rapid onset of action and low variability. These technologies are being leveraged to develop prescription and over-the-counter cannabinoid medicines for the U.S. and global markets. Receptor Life Sciences, Inc. (RLS), is a subsidiary of RHI focused on FDA-regulated drug development. RLS will use RHI drug delivery technologies to develop cannabinoid medicines for multiple therapeutic indications. For more information visit www.receptorlife.com. |
|
|
|
Post by dh4mizzou on Jan 19, 2021 11:09:47 GMT -5
It would be nice if they could include a timeline across the top as well. |
|
|
|
Post by mango on Jan 19, 2021 11:48:08 GMT -5
Sweet. Looks like we have two Technosphere applications so far. Cannabidiol Technosphere for acute panic attack and inhaled minor cannabinoids for various medical conditions. Some minor cannabinoids include, CBG, CBC, CBN, THVC, THC-A, CBD-A, Delta-8-THC. There’s many, many more though. Even though Receptor does not specify Technosphere for the application of these inhaled minor cannabinoids, I assume that is what they’ll be utilizing. |
|
|
|
Post by hellodolly on Jan 19, 2021 12:38:08 GMT -5
Based on the new CEO's track record, the next press release will say "RLS is being acquired by..." ...MNKD! ...UTHR! |
|
|
|
Post by uvula on Jan 19, 2021 12:55:10 GMT -5
Based on the new CEO's track record, the next press release will say "RLS is being acquired by..." ...MNKD! ...UTHR! More likely that all 3 will be packaged together and gobbled up by a large company. |
|
|
|
Post by mango on Jan 19, 2021 13:08:57 GMT -5
More likely that all 3 will be packaged together and gobbled up by a large company. Who will buy RLS? GW? Or will RLS buy up some smaller companies? |
|
